TOVX
Theriva Biologics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
—
−4.58%
shares held · 10 largest managers
Theriva Biologics has 7 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceVCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.
SentenceVCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.
TOVX 10-Kaccession 0001104659-26-026767
SentenceIn February 2019, VCN entered into a Clinical Trial Agreement with Catalan Institute of Oncology (ICO) (Spain) to conduct an investigator sponsored Phase 1 clinical study to evaluate the safety, tolerability and RP2D of a single intravenous injection of VCN-01 combined with durvalumab in two administration regimens
TOVX 10-Kaccession 0001104659-26-026767
SentenceVCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.
TOVX 10-Kaccession 0001104659-26-026767
SentenceOn March 4, 2016, VCN entered into a License Agreement (the "IDIBELL/ICO License Agreement") with IDIBELL and the ICO, for the exclusive license of the right to use a family of patents whose priority application is European patent application EP 14 38 2162.7 titled "Adenovirus comprising an albumin-binding moiety".
TOVX 10-Kaccession 0001104659-26-026767
SentenceVCN-01, VCN-11, and VCN - 12) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, Recipharm Advanced Bio, Fujifilm Diosynth and others.
TOVX 10-Kaccession 0001104659-26-026767
SentenceIn the second quarter of 2021, VCN entered into a Clinical Trial Agreement with the University of Leeds (UK) to sponsor a proof-of-concept Phase 1 clinical study to evaluate whether intravenously administered VCN-01 can cross the blood-brain barrier and infect the target brain tumor.
TOVX 10-Kaccession 0001104659-26-026767
SentenceIn February 2026, we entered into a license agreement (the "Rasayana License Agreement") with Rasayana Therapeutics, Inc. ("Rasayana"), pursuant to which we granted Rasayana an exclusive worldwide license with the right to grant sublicenses to research, develop, manufacture and commercialize any Product
TOVX 10-Kaccession 0001104659-26-026767
Theriva Biologics, Inc.
0.17
Linked news
NewsExpected move
No implied move.